Study summary

Tocilizumab slowed lung function loss in scleroderma lung disease

Tocilizumab meta-analysis · Five studies · Published February 2024, Annals of the American Thoracic Society; FDA approved for SSc-ILD 2021

66%lower risk of a 10%+ drop in lung capacity

What was tested

Tocilizumab, an antibody blocking the inflammatory signal IL-6, for systemic sclerosis-associated interstitial lung disease, pooled for an American Thoracic Society guideline.

What they found

Lung capacity (FVC) fell 241 ml less than with placebo at 48 weeks.
Risk of losing more than 10% of predicted lung capacity was 66% lower.

What it means

Supports tocilizumab for early, inflammatory scleroderma lung disease.

Ann Am Thorac Soc, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.